NewsOrganoclick intends to undertake a directed share issue for financing potential acquisitions and the company’s continued growth

At large demand, Serendipity Ixora may make shares available to enable greater institutional participation

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONG KONG, SINGAPORE OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

OrganoClick announces its intention to undertake a directed share issue of up to approximately SEK 40 million. In the event of a high demand, additional allocation may also be made through Serendipity Ixora, which has made part of its shares available to enable an increased transaction size and greater institutional participation.

OrganoClick (“OrganoClick” or the “Company“) intends to offer new shares through a directed share issue of up to approximately SEK 40 million (the “Private Placement“). The possible Private Placement is directed to Swedish and international investors and is, inter alia, subject to the board of directors of OrganoClick (the “Board”) resolving to issue new shares following the completion of the Private Placement (in a so called accelerated book building process) that will be carried out by Pareto Securities AB (“Pareto Securities”).

The subscription price for the shares in the Private Placement will be determined in the book building process. The book building process will begin no earlier than 17:31 (CET) on September 19, 2017, and end before the commencement of trading on Nasdaq First North on September 20, 2017. The minimum order will be set at the number of shares corresponding to EUR 100,000. The book building process for the Private Placement may close earlier or later at the discretion of the Company and the Company can choose to cancel the book building in its sole discretion for any reasons and at any time.

The rationale for carrying out the Private Placement is to enable financing of potential acquisitions, as the Company is currently in active discussions regarding acquisitions, and wants to secure financing for the Company’s continued growth.

The reason for deviating from the shareholders’ preferential rights by conducting a directed new share issue is to broaden the shareholder base and that a directed share issue means lower costs and a faster process which collectively and with sufficient strength indicate that it is in the Company’s and the shareholders’ interest that the share issue is made with deviation from the shareholders’ preferential rights.

Serendipity Ixora AB (publ) (“Serendipity Ixora“), has announced that in the event of high demand, Serendipity Ixora will make maximum 5,000,000 shares available, at the same price as determined in the book building process, to enable an increased transaction size and greater institutional participation. Serendipity Ixora has entered into a 90-day lock-up undertaking with Pareto Securities AB for the shares they do not sell in connection with the Private Placement.

Pareto Securities has been appointed as sole bookrunner and lead manager in connection with the Private Placement.

 

For further information please contact:
Mårten Hellberg, CEO
08-684 001 10
marten.hellberg@organoclick.com

This information is information that OrganoClick AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 17:31 CET on September 19, 2017. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

 

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipient of this press release is responsible for using the information in this press release in accordance with applicable law in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

This press release is not a prospectus for the purposes of Directive 2003/71/EC as amended through Directive 2010/73/EU. The Company has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus or other offering document has been or will be prepared in connection with the directed share issue.